This company listing is no longer active
| Snowflake Score | |
|---|---|
| Valuation | 4/6 |
| Future Growth | 2/6 |
| Past Performance | 0/6 |
| Financial Health | 0/6 |
| Dividends | 0/6 |
IMV Inc. Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | CA$1.12 |
| 52 Week High | CA$13.10 |
| 52 Week Low | CA$0.62 |
| Beta | 1.38 |
| 1 Month Change | 0% |
| 3 Month Change | 60.00% |
| 1 Year Change | -89.72% |
| 3 Year Change | -96.97% |
| 5 Year Change | -98.41% |
| Change since IPO | -96.96% |
Recent News & Updates
Shareholder Returns
| IMV | CA Biotechs | CA Market | |
|---|---|---|---|
| 7D | 0% | -1.1% | 0.7% |
| 1Y | -89.7% | -38.2% | 5.5% |
Return vs Industry: IMV underperformed the Canadian Biotechs industry which returned 27.7% over the past year.
Return vs Market: IMV underperformed the Canadian Market which returned -5.1% over the past year.
Price Volatility
| IMV volatility | |
|---|---|
| IMV Average Weekly Movement | 15.5% |
| Biotechs Industry Average Movement | 13.4% |
| Market Average Movement | 9.1% |
| 10% most volatile stocks in CA Market | 18.2% |
| 10% least volatile stocks in CA Market | 3.0% |
Stable Share Price: IMV's share price has been volatile over the past 3 months.
Volatility Over Time: IMV's weekly volatility (15%) has been stable over the past year, but is still higher than 75% of Canadian stocks.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 2000 | 63 | Andrew Hall | www.imv-inc.com |
IMV Inc. operates as a clinical-stage immuno-oncology company. The company develops a portfolio of therapies based on DPX its immune-educating technology platform for treatment of solid and hematological cancers. The company’s lead drug candidate includes maveropepimut-S, a DPX-based immunotherapy that targets survivin-expressing cells that is Phase II clinical trials for diffuse large B cell lymphoma; ovarian cancer; and bladder, liver, and MSI-H solid tumors, as well as in Phase I clinical trial for breast cancer.
IMV Inc. Fundamentals Summary
| IMV fundamental statistics | |
|---|---|
| Market cap | CA$13.12m |
| Earnings (TTM) | -CA$50.71m |
| Revenue (TTM) | n/a |
0.0x
P/S Ratio-0.3x
P/E RatioIs IMV overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| IMV income statement (TTM) | |
|---|---|
| Revenue | US$0 |
| Cost of Revenue | US$23.28m |
| Gross Profit | -US$23.28m |
| Other Expenses | US$14.71m |
| Earnings | -US$37.99m |
Last Reported Earnings
Dec 31, 2022
Next Earnings Date
n/a
| Earnings per share (EPS) | -3.24 |
| Gross Margin | 0.00% |
| Net Profit Margin | 0.00% |
| Debt/Equity Ratio | -415.9% |
How did IMV perform over the long term?
See historical performance and comparison